Phosphodiesterase-5 Enzyme Inhibitor

8 Drugs classified under this drug class

Phosphodiesterase-5 Enzyme Inhibitor. Tadalafil 2.5, 5, 10, 20 mg.
F.C. TABS: 4 x 10 mg; 4, 8 x 20
mg. On-demand: 10 mg or 20 mg,
depend. response, 30 mins. - 12 hrs
bef. Sexual activity. Effic. may persist
for up to 36 hrs. Max: 1 dose dly, but
dly use not recommend. Child: Under
18 yrs: Not recommend.
F.C. TABS: 28 x 2.5 mg, 5 mg. Onceaday:
For men who anticipate freq. use
(min. 2 x wkly): 2.5 mg/5 mg 1 x dly,
depend. on individ. tolerabil. Reassess period. See lit.
Treatment of erectile dysfunction
(ED) in adult men. Also indicated for the
treatment of the signs and symptoms of
benign prostatic hyperplasia (BPH), also
indicated for the treatment of ED and the
signs and symptoms of BPH (ED/BPH).
CIALIS is not indicated for use by women.
C/I: Co-adminis. nitrates. Card.dis. I,Uns.
ang. uncont. Arrhythmias,
hypotens. Uncontr. Hypertens. Use by
women, see lit.

Phosphodiesterase-5 Enzyme Inhibitor. Vardenafil (as HCl) 5 mg, 10 mg, 20 mg.
TABS: 2, 4 x 5 mg, 10 mg; 8 x 20 mg.
Recommend. start. dose: 10 mg 25-60 mins. bef. intercourse. May incr. to 20 mg or decr. to 5 mg. Max: 20 mg/day.
Max: 1 x dly. Over 65 yrs: Initial: 5 mg.
Tmt. of erectile dysfunct. In order for the drug to be effective, sexual stimul. is required. Not indicated for use by women.
C/I: Hypersens. Co-admin. with nitrates, nitric oxide donors (e.g. as amyl nitrite). Pts. who have loss of vision in one eye because of non-arteritic anter. ischem. optic neuropathy (NAION), regardless of whether this episode was in connect. or not with prev. phosphodiesterase 5 (PDE5) inhib.
Meds. products for the tmt. of erectile dysfunct. should general. not be used in men for whom sex. activ. is inadvis. (e.g. pts. with sev. cardiovasc. disord. such as unstab. angina or sev. card. fail. [NYHA III or IV]).
Severe hep. impair. (Child-Pugh C), end stage ren. dis. requir. dialys., hypotens. (BP 90/50 mmHg), Recent hist. of stroke or MI (within the last 6 mnths.), unstab. ang. and known hered. retin. degenerate. disord. such as retinit. pigmentosa.
Concom. use with the potent CYP3A4 inhib. ketoconazole & itraconazole (oral form) is contraind. in men older than 75 yrs.
Concom. use with HIV protease inhib. such as ritonavir & indinavir. Co-admin. of PDE5 inhib., with guanylate cyclase stimulat., (e.g. riociguat).

Phosphodiesterase-5 Enzyme Inhibitor. Vardenafil 10 mg.
ORODISPERSIBLE TABS: 4. Recommend. dose: 1 orodisp. tab. 25-60 mins. bef. intercourse. Max: 1 x dly (with/out food).
Tmt. of erectile dysfunct. In order for the drug to be effective, sexual stimul. is required. Not indicated for use by women.
C/I: Hypersens. Co-admin. with nitrates, nitric oxide donors (e.g. as amyl nitrite). Pts. who have loss of vision in one eye because of non-arteritic anter. ischem. optic neuropathy (NAION), regardless of whether this episode was in connect. or not with prev. phosphodiesterase 5 (PDE5) inhib.
Meds. products for the tmt. of erectile dysfunct. should general. not be used in men for whom sex. activ. is inadvis. (e.g. pts. with sev. cardiovasc. disord. such as unstab. angina or sev. card. fail. [NYHA III or IV]).
Severe hep. impair. (Child-Pugh C), end stage ren. dis. requir. dialys., hypotens. (BP 90/50 mmHg), Recent hist. of stroke or MI (within the last 6 mnths.), unstab. ang. and known hered. retin. degenerate. disord. such as retinit. pigmentosa.
Concom. use with the potent CYP3A4 inhib. ketoconazole & itraconazole (oral form) is contraind. in men older than 75 yrs.
Concom. use with HIV protease inhib. such as ritonavir & indinavir.
Co-admin. of PDE5 inhib., with guanylate cyclase stimulat., (e.g. riociguat).

Phosphodiesterase-5 Enzyme Inhibitor. Sildenafil 25 mg.
Susp. for oral spray 20 ml. Each actuat. delivers 0.5 ml susp., contain. 12.5 mg sildenafil
Dose is 2 mL (4 act.), equiv. to 50 mg of sildenafil taken as needed, approx. one hour before sexual activ. Based on effic. and tolerab., dose may be incr. to 4 mL (8 act.), equiv. to 100 mg, or decr. to 1 mL (2 act.), equiv. to 25 mg of sildenafil. Max. dose is 4 mL (8 act.), equiv. to 100 mg of sildenafil. Max. dosing freq. is 1/d.
In adult men with erectile dysfunction.
C/I: Hypersens. Co-administr. with nitric oxide donors (such as amyl nitrite) or nitrates in any form. Co-administr. with guanylate cyclase stimul., such as riociguat, as it may lead to symptom. Hypotension. Not  to be used in men for whom sexual act. is inadvisable (e.g. pts. with sev. CV disord. such as unstable angina or sev. HF). Contraindic. in ptts. who have loss of vision in one eye due to non-arteritic anterior ischaemic optic neuropathy (NAION). Safety has not been studied in the follow. sub-groups of pts. and use is contraindic. in these pts: sev. hepatic impairm., hypotension (blood pressure <90/50 mmHg), recent hist. of stroke or MI and known heredit. degenerat. retinal disord. such as retinitis pigmentosa.

Phosphodiesterase-5 Enzyme Inhibitor. Sildenafil 25, 50, 100 mg.
F.C. TABS.: 4, 8 x 50 mg, 100 mg.
To be taken once dly. 50 mg as needed
approx. 1 h bef. sexual act.; may be
incr. to 100 mg or decreas. to 25 mg.
Max.:100 mg. May be taken before or
after meal.
Impair. renal funct.: mild-mod.: no
dosage adjust. req.; Sev. renal impair.:
25 mg should be consid. Impair. hepatic
funct.: A dose of 25 mg should be
consid.
Elderly: Dosage adjust. is required.
Tmt. of erectile dysfunct.
C/I: Known hypersens. to product; pts.
concur. using nitric oxide donors (such
as amyl nitrite), organic nitrates, or
organic nitrites in any form either
regularly or intermittently; under 18
years; sev. cardiovascular or sev. liver
disease; recent history of MI ,stroke, or
pts. who suffer from hypotension; pts.
who have loss of vision in one eye
because of non-arteritic anterior
ischemic optic neuropathy (NAION);
hereditary degener. retinal dis. such as
retinitis pigmentosa; not intended to be
used in women.

Phosphodiesterase-5 Enzyme Inhibitor. Tadalafil 20 mg.
TABS.: 20mg × 1, 4, 8.
1/2 to 1 tab., at least 30 min. prior to sexual contact.
Not more than 1 tab./ d.
May be taken at any time during the
day. The effect may last up to 36 hrs.
Not for dly. use.
Tmt. of erectile dysfunct. in men.
C/I: Hypersens.
Pts. under any form of organic nitrate ther.
Men with cardiac. dis. to whom sexual. activ. is not advisable.
Pts. with MI within the last 90 d.
Pts. with unstab. angina.or angina occur. during sex. intercourse.
Pts. with NYHA Class 2 or greater heart fail. in the last 6 mnths.
Pts. with uncontroll. arrhythm., hypotens.(<90/50 mmHg), or uncontrol. hypertens.
Pts. with a stroke within the last 6 mnths.
Pts. with loss of vision in one eye due to non-arteritic anterior ischemic optic neuropath. (NAION), regardless of whether this episode was in connect.or not with previous PDE5 inhib.expos.
Co-admin.of PDE5 inhib.